Swiss Acino, Saudi’s Alpha partner to attain Saudi National Vision 2030

Swiss Acino, Saudi’s Alpha partner to attain Saudi National Vision 2030

Acino, a Swiss-based pharmaceutical company, has partnered with Saudi Arabia’s Alpha Pharma to meet the aspirations of the Saudi health sector transformation program launched as part of National Vision 2030.

The partnership agreement was signed by Dr. Andrew Bird, General Manager and Head of Region, Middle East, Turkey, and Africa, Acino, and Mr. Yaser Y. Naghi, CEO of Cigalah Health Care company and its subsidiary Alpha Pharma.

HE Abdullah Al Masoud, Saudi Commercial Attaché to Switzerland, Mr. Steffen Saltofte, CEO of Acino, Mr. Fahad Al Otaibi, Acino’s Country Manager for Saudi Arabia and Dr. Murad Al Saggaf, General Manager, Alpha Pharma were also present at the occasion.

Commenting on the partnership, H.E. Abdullah Al Masoud remarked that, “Partnerships like these are a step in the right direction towards achieving the Saudi Vision 2030 and the Health Sector Transformation Programme. We commend the efforts of Acino in expanding its presence in the Kingdom, and striking collaborations with organizations such as Alpha Pharma to increase access to treatments for patients who need them most.”

Saudi Arabia’s health sector transformation program, which is considered a key component of the National Transformation Program, focuses on improving the quality and effectiveness of health care and optimizing treatment outcomes. In